Abstract:The hemoglobin-A1c test, measuring the ratio of glycated hemoglobin (HbA1c) to hemoglobin (Hb) levels, has been a standard assay in diabetes diagnosis that removes the day-to-day glucose level variation. Currently, the HbA1c test is restricted to hospitals and central laboratories due to the laborious, time-consuming whole blood processing and bulky instruments. In this paper, we have developed a microfluidic device integrating dual CMOS polysilicon nanowire sensors (MINS) for on-chip whole blood processing and simultaneous detection of multiple analytes. The micromachined polymethylmethacrylate (PMMA) microfluidic device consisted of a serpentine microchannel with multiple dam structures designed for non-lysed cells or debris trapping, uniform plasma/buffer mixing and dilution. The CMOS-fabricated polysilicon nanowire sensors integrated with the microfluidic device were designed for the simultaneous, label-free electrical detection of multiple analytes. Our study first measured the Hb and HbA1c levels in 11 clinical samples via these nanowire sensors. The results were compared with those of standard Hb and HbA1c measurement methods (Hb: the sodium lauryl sulfate hemoglobin detection method; HbA1c: cation-exchange high-performance liquid chromatography) and showed comparable outcomes. Finally, we successfully demonstrated the efficacy of the MINS device's on-chip whole blood processing followed by simultaneous Hb and HbA1c measurement in a clinical sample. Compared to current Hb and HbA1c sensing instruments, the MINS platform is compact and can simultaneously detect two analytes with only 5 μL of whole blood, which corresponds to a 300-fold blood volume reduction. The total assay time, including the in situ sample processing and analyte detection, was just 30 minutes. Based on its on-chip whole blood processing and simultaneous multiple analyte detection functionalities with a lower sample volume requirement and shorter process time, the MINS device can be effectively applied to real-time diabetes diagnostics and monitoring in point-of-care settings.

Top-down proteomics of a drop of blood for diabetes monitoring.

Multi-parameter Biosensor for Diabetes Monitoring

Label-free electrochemical detection of glycated hemoglobin (HbA1c) and C-reactive protein (CRP) to predict the maturation of coronary heart disease due to diabetes

Using a Glucose Meter to Quantitatively Detect Disease Biomarkers Through a Universal Nanozyme Integrated Lateral Fluidic Sensing Platform.

Simultaneous electrochemical detection of glycated and human serum albumin for diabetes management

A microfluidic device integrating dual CMOS polysilicon nanowire sensors for on-chip whole blood processing and simultaneous detection of multiple analytes

Quantitative, single-step dual measurement of hemoglobin A1c and total hemoglobin in human whole blood using a gold sandwich immunochromatographic assay for personalized medicine

A Smartphone-Assisted Microfluidic Chemistry Analyzer Using Image-Based Colorimetric Assays for Multi-Index Monitoring of Diabetes and Hyperlipidemia.

Point-of-care Testing of Protein Biomarkers by Integrating a Personal Glucose Meter with a Concatenated DNA Amplifier

Point-of-care testing of four chronic disease biomarkers in blood based on a low cost and low system complexity microfluidic chip with integrated oxygen-sensitive membrane

Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning

Integrated Strategy for Discovery and Validation of Glycated Candidate Biomarkers for Hemodialysis Patients with Cardiovascular Complications.

Spatial localization of β-unsaturated aldehyde markers in murine diabetic kidney tissue by mass spectrometry imaging

Serum integrative omics reveals the landscape of human diabetic kidney disease

AIE multifunctional probe empowering colorimetric-fluorescence dual-mode biosensor for early diabetic screening

Next generation plasma proteome profiling to monitor health and disease

Longitudinal blood microsampling and proteome monitoring facilitate timely intervention in experimental type 1 diabetes

Identification of Dysregulated Complement Activation Pathways Driven by N-Glycosylation Alterations in T2D Patients

Biomarker Profiling with Targeted Metabolomic Analysis of Plasma and Urine Samples in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease

Advances in Current Diabetes Proteomics: from the Perspectives of Label- Free Quantification and Biomarker Selection

Detection of Protein Biomarker Using a Blood Glucose Meter.